๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐๐๐ฅ๐ฅ & ๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐๐ง๐ฎ๐๐๐๐ญ๐ฎ๐ซ๐ข๐ง๐ ๐๐๐ซ๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐, ๐๐ก๐๐ซ๐ & ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐๐-๐๐๐๐)
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dX7ACeFM
The North America Cell & Gene Therapy Manufacturing Services Market revenue is projected to witness exponential growth during 2020-2035. Supported by accelerating FDA approvals, investment flows, and expanding contract manufacturing capacities, the market is expected to rise from USD 1,600 Million in 2020 to over USD 8,300 Million by 2035. Key growth drivers include the advancement of personalized medicine and consistent investment in scalable manufacturing platforms to address rising demand across major therapeutic areas.
Key Drivers
Rising FDA approvals and clinical trial activities for cell and gene therapies in North America are accelerating demand for specialized manufacturing services. For instance, in June 2024, Bristol Myers Squibb expanded its cell therapy manufacturing capacity in the US to meet increased patient demand.
Strong investments and collaborations between biotechs and contract manufacturing organizations are streamlining production cycles. Recently, Thermo Fisher Scientific announced an expanded partnership with bluebird bio (July 2024) for commercial gene therapy manufacturing.
Key Trends
Adoption of automation and digital bioprocessing is enhancing the scalability and consistency of cell and gene therapy manufacturing. WuXi AppTec launched a new digital manufacturing suite in June 2024 to optimize operations and turnaround time.
Increasing outsourcing of plasmid DNA and viral vector production to contract manufacturers—Lonza reported a 40% increase in viral vector contracts in early 2024, indicating a shift toward deeper collaboration with therapy developers.
Market Insights & Segmentation
Type (Allogeneic, Autologous, Viral Vector, Non-viral Vector, Plasmid DNA, Others),
Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases, Others),
Distribution Channels (Direct Tenders, Third-Party Distributors, Online Platforms, Others),
Technology (Gene Editing, Cell Expansion, Viral Vector Production, Cryopreservation, Automation, Others),
Organization Size (Small, Medium, Large)
Key Market Companies
Thermo Fisher Scientific, Lonza, Catalent, WuXi AppTec, Charles River Laboratories, Oxford Biomedica, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Bluebird Bio, Cell and Gene Therapy Catapult, uniQure, Novartis, BioNTech, Bristol Myers Squibb, Editas Medicine
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/dem4aSgd
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dX7ACeFM
The North America Cell & Gene Therapy Manufacturing Services Market revenue is projected to witness exponential growth during 2020-2035. Supported by accelerating FDA approvals, investment flows, and expanding contract manufacturing capacities, the market is expected to rise from USD 1,600 Million in 2020 to over USD 8,300 Million by 2035. Key growth drivers include the advancement of personalized medicine and consistent investment in scalable manufacturing platforms to address rising demand across major therapeutic areas.
Key Drivers
Rising FDA approvals and clinical trial activities for cell and gene therapies in North America are accelerating demand for specialized manufacturing services. For instance, in June 2024, Bristol Myers Squibb expanded its cell therapy manufacturing capacity in the US to meet increased patient demand.
Strong investments and collaborations between biotechs and contract manufacturing organizations are streamlining production cycles. Recently, Thermo Fisher Scientific announced an expanded partnership with bluebird bio (July 2024) for commercial gene therapy manufacturing.
Key Trends
Adoption of automation and digital bioprocessing is enhancing the scalability and consistency of cell and gene therapy manufacturing. WuXi AppTec launched a new digital manufacturing suite in June 2024 to optimize operations and turnaround time.
Increasing outsourcing of plasmid DNA and viral vector production to contract manufacturers—Lonza reported a 40% increase in viral vector contracts in early 2024, indicating a shift toward deeper collaboration with therapy developers.
Market Insights & Segmentation
Type (Allogeneic, Autologous, Viral Vector, Non-viral Vector, Plasmid DNA, Others),
Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Rare Diseases, Infectious Diseases, Others),
Distribution Channels (Direct Tenders, Third-Party Distributors, Online Platforms, Others),
Technology (Gene Editing, Cell Expansion, Viral Vector Production, Cryopreservation, Automation, Others),
Organization Size (Small, Medium, Large)
Key Market Companies
Thermo Fisher Scientific, Lonza, Catalent, WuXi AppTec, Charles River Laboratories, Oxford Biomedica, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Bluebird Bio, Cell and Gene Therapy Catapult, uniQure, Novartis, BioNTech, Bristol Myers Squibb, Editas Medicine
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/dem4aSgd
381 Views
